MedTrace Logo

Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer

NCT00336141 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-05-21

No results posted yet for this study

Summary

This protocol will investigate the use of vorinostat (suberoylanilide hydroxamic acid - SAHA) in combination with infusional 5-FU and leucovorin for the treatment of metastatic colorectal cancer patients who have failed standard 5FU regimens.

Conditions

Interventions

DRUG

Suberoylanilide hydroxamic acid

400 mg QD (every day) for five days, followed by 9 days of no vorinostat

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00336141 on ClinicalTrials.gov